Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | MDM4 | O15151 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 2/20 | 0.58 |
| ▸ | TLR2 | O60603 | 2/20 | 0.57 |
| ▸ | CASP3 | P42574 | 2/20 | 0.55 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.52 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30338216 | 1.00 | KMT2A (0.58) | KMT2AMDM4TP53TLR2CASP3 | |
| SCHEMBL29908078 | 1.00 | KMT2A (0.58) | KMT2AMDM4TP53TLR2CASP3 | |
| SCHEMBL12254866 | 1.00 | KMT2A (0.58) | KMT2AMDM4TP53TLR2CASP3 | |
| SCHEMBL29400089 | 1.00 | KMT2A (0.58) | KMT2AMDM4TP53TLR2CASP3 | |
| SCHEMBL1025352 | 1.00 | KMT2A (0.58) | KMT2AMDM4TP53TLR2CASP3 | |
| SCHEMBL14997839 | 1.00 | KMT2A (0.58) | KMT2AMDM4TP53TLR2CASP3 | |
| SCHEMBL12658035 | 0.95 | PTPN1 (0.58) | KMT2AMDM4TP53TLR2CASP3 | |
| SCHEMBL14719947 | 0.93 | KMT2A (0.57) | KMT2AMDM4TP53TLR2CASP3 | |
| SCHEMBL22712859 | 0.93 | TLR2 (0.54) | KMT2AMDM4TP53TLR2CASP3 | |
| D-Glutamate SCHEMBL28574794 | 0.93 | MDM4 (0.52) | KMT2AMDM4TP53TLR2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 756 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116848-A1 | Synthesis of an Intermediate and Its Use for the Preparation of GLP-1R/GIPR Agonists | CARMOT THERAPEUTICS INC. (US) | 2026-04-30 | — | — | US | claimed |
| US-12600759-B2 | Process of preparation of glucagon-like peptide-1 (GLP-1) receptor agonists and their analogs | ENZENE BIOSCIENCES LIMITED (IN) | 2026-04-14 | — | — | US | claimed |
| US-20250326796-A1 | PEPTIDE ANALOG WITH ANTI-INFLAMMATORY ACTIVITY AND ITS PREPARATION METHOD AND APPLICATION | SHANGHAI UNIVERSITY (CN) | 2025-10-23 | — | — | US | claimed |
| CN-118994311-B | Preparation method of decapeptide-4, composition for preventing alopecia and hair product prepared from decapeptide-4 compound plant extract | 南京斯拜科生物科技股份有限公司 | 2025-06-17 | — | — | CN | claimed |
| WO-2025098464-A1 | INTERMEDIATE FOR PREPARING GLUCAGON AND GLP-1 DUAL AGONIST AND PREPARATION METHOD THEREFOR | INNOVENT BIOLOGICS (SUZHOU) CO., LTD. (CN) | 2025-05-15 | — | — | WO | claimed |
| CN-119978100-A | Tizepa Process for producing peptide | 四川吉晟生物医药有限公司 | 2025-05-13 | — | — | CN | claimed |
| CN-119954690-A | Protection of amino acid side chains by host-guest affinity molecules in peptide synthesis | 马涌 | 2025-05-09 | — | — | CN | claimed |
| CN-119959197-A | Interaction analysis method of 8:2 fluorotelomer alcohol-target protein based on confocal fluorescence imaging | 华中农业大学 | 2025-05-09 | — | — | CN | claimed |
| WO-2025088147-A1 | THERANOSTIC PSMA-TARGETING LIGANDS FOR THE DIAGNOSIS AND TREATMENT OF PSMA-EXPRESSING CANCERS AND THEIR SOLID PHASE SYNTHESIS | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2025-05-01 | — | — | WO | claimed |
| CN-119751556-A | Epithalon vitamin B6 coupled derivative and preparation method and application thereof | 润辉生物技术（威海）有限公司 | 2025-04-04 | — | — | CN | claimed |
| CN-114349823-A | Double-targeting multifunctional peptoid compound and preparation method and application thereof | 杭州禾泰健宇生物科技有限公司 | 2022-04-15 | — | — | CN | claimed |
| CN-112175067-B | Preparation method of teduglutide | 深圳市星银医药有限公司 | 2022-04-15 | — | — | CN | claimed |
| CN-112390859-B | Self-assembly polypeptide probe for identifying Caspase protein, preparation method and application | 南开大学 | 2022-04-05 | — | — | CN | claimed |
| CN-113135988-B | Preparation method of thymosin beta 4 | 润辉生物技术（威海）有限公司 | 2022-04-01 | — | — | CN | claimed |
| CN-114262358-A | Preparation method of glutamine dipeptide | 苏州天马医药集团天吉生物制药有限公司 | 2022-04-01 | — | — | CN | claimed |
| CN-113880936-B | Solid-phase synthesis method of abamectin | 浙江湃肽生物有限公司南京分公司 | 2022-03-29 | — | — | CN | claimed |
| CN-109678927-B | Glutathione total synthesis method based on phosphate carrier | 西北工业大学 | 2022-03-15 | — | — | CN | claimed |
| CN-110294800-B | Preparation method of somaglutide | 齐鲁制药有限公司 | 2022-03-04 | — | — | CN | claimed |
| CN-114044813-A | Preparation and purification method of procatide | 浙江湃肽生物有限公司南京分公司 | 2022-02-15 | — | — | CN | claimed |
| CN-114010798-A | Enzymatic self-assembly and disassembly curcumin drug-loaded hydrogel precursor and application thereof | 安徽大学 | 2022-02-08 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116848-A1 | Synthesis of an Intermediate and Its Use for the Preparation of GLP-1R/GIPR Agonists | GLP1R, GIPR, CCKBR | KMT2A 2588/4885MDM4 4227/4885TP53 4727/4885 |
| US-20250326796-A1 | PEPTIDE ANALOG WITH ANTI-INFLAMMATORY ACTIVITY AND ITS PREPARATION METHOD AND APPLICATION | STING1, CGAS, VIP | KMT2A 4850/4885MDM4 1661/4885TP53 1709/4885 |
| US-12600759-B2 | Process of preparation of glucagon-like peptide-1 (GLP-1) receptor agonists and their analogs | GLP1R, GIPR, GCG | KMT2A 2737/4885MDM4 3864/4885TP53 4243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.